ID: ALA606986

Max Phase: Preclinical

Molecular Formula: C30H35NO5

Molecular Weight: 489.61

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C1CC[C@@]2(OCCCc3ccccc3)[C@H]3Cc4ccc(O)c5c4[C@@]2(CCN3CC2CCCO2)[C@H]1O5

Standard InChI:  InChI=1S/C30H35NO5/c32-23-11-10-21-18-25-30(35-17-4-8-20-6-2-1-3-7-20)13-12-24(33)28-29(30,26(21)27(23)36-28)14-15-31(25)19-22-9-5-16-34-22/h1-3,6-7,10-11,22,25,28,32H,4-5,8-9,12-19H2/t22?,25-,28+,29+,30-/m1/s1

Standard InChI Key:  WYNXSVPUCGXOSY-WFGIOELNSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 489.61

Molecular Weight (Monoisotopic): 489.2515

AlogP: 3.95

#Rotatable Bonds: 7

Polar Surface Area: 68.23

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 10.08

CX Basic pKa: 8.44

CX LogP: 4.26

CX LogD: 3.32

Aromatic Rings: 2

Heavy Atoms: 36

QED Weighted: 0.59

Np Likeness Score: 1.14

References

1. Greiner E, Spetea M, Krassnig R, Schüllner F, Aceto M, Harris LS, Traynor JR, Woods JH, Coop A, Schmidhammer H..  (2003)  Synthesis and biological evaluation of 14-alkoxymorphinans. 18. N-substituted 14-phenylpropyloxymorphinan-6-ones with unanticipated agonist properties: extending the scope of common structure-activity relationships.,  46  (9): [PMID:12699394] [10.1021/jm021118o]

Source

Source(1):

• Scientific Literature